AAIS
NBIX icon

ABN AMRO Investment Solutions’s Neurocrine Biosciences NBIX Stock Holding History

ABN AMRO Investment Solutions’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$865K Buy
5,133
+2,093
+69% +$311K 0.01% 542
2026
Q1 		$400K Buy
3,040
+334
+12% +$44.3K 0.01% 577
2025
Q4 		$384K Buy
+2,706
New +$392K 0.01% 523

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

ABN AMRO Investment Solutions's NBIX Position: Q2 2026 in Review

ABN AMRO Investment Solutions increased its Neurocrine Biosciences (NBIX) stake by 69% in Q2 2026, buying an estimated $311K and bringing the position to 5,133 shares worth $865K. The position accounts for 0.01% of the portfolio, ranked #542.

ABN AMRO Investment Solutions first reported a position in NBIX in Q4 2025 and has held it in 3 quarters since. 777 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • ABN AMRO Investment Solutions held 5,133 shares of Neurocrine Biosciences worth $865K as of Q2 2026.
  • ABN AMRO Investment Solutions bought 2,093 Neurocrine Biosciences shares in Q2 2026, an estimated $311K.
  • Neurocrine Biosciences made up 0.01% of ABN AMRO Investment Solutions's portfolio in Q2 2026, its #542 holding.
  • ABN AMRO Investment Solutions first reported a position in Neurocrine Biosciences in Q4 2025 and has held it in 3 quarters since.
  • 777 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on ABN AMRO Investment Solutions's 13F filing for Q2 2026, filed 23 Jul 2026.